United Therapeutics' oral treprostinil fails Phase III PAH trial
This article was originally published in Scrip
Executive Summary
United Therapeutics' oral treprostinil has failed its pivotal Phase III trial, FREEDOM-C, testing it as an adjunctive treatment in pulmonary arterial hypertension (PAH).